Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NY9Q
|
||||
| Former ID |
DIB006422
|
||||
| Drug Name |
MK2 inhibitors
|
||||
| Synonyms |
MK2 inhibitors (autoimmune disease); MAPKAPK2 inhibitors (autoimmune disease), Novartis; MK2 inhibitors (autoimmune disease), Novartis; Mitogen-activated protein kinase activated protein kinase 2 inhibitors (autoimmune disease), Novartis
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Investigative | [552072] | ||
| Company |
Novartis AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1nc(cc2c3c(CCc12)c1c([nH]3)CC2(CC2)NC1=O)c1cnc(cc1)F
|
||||
| Target and Pathway | |||||
| Target(s) | MAPKAP kinase 2 | Target Info | Inhibitor | [543553] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| Serotonin HTR1 Group and FOS Pathway | |||||
| p38 MAPK Signaling Pathway | |||||
| MAPK Signaling Pathway | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| MAP kinase activation in TLR cascade | |||||
| Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||||
| Arachidonic acid metabolism | |||||
| Structural Pathway of Interleukin 1 (IL-1) | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| IL-1 signaling pathway | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| MAPK targets/ Nuclear events mediated by MAP kinases | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.